Roka Bioscience, Inc. (NASDAQ:ROKA) reported its last quarter results on 11/07/2016. This Company belongs to Medical sector.
In the last trading session, The Company traded 1.67 Million shares. The Stock Market opened sessions at 5.72 and closed at 6. There was a stock increase by 22.45 percent.
According to Yahoo Finance, the price target for the company which analysts are aiming is 10. The 1-year price target of the company is 10.
Investors expected a price target of -1.14 for this quarter. Zacks Investment Research gave Roka Bioscience, Inc. (NASDAQ:ROKA) a rating of 1 on a scale of 1 to 5. Here, 1 indicates a Strong Buy and 5 indicates a Strong Sell.
For the quarter ending 08/05/2016, The Analyst projected that the company could deliver EPS of -4.75 while the company provided its Actual EPS of -5.6 showing a difference of -0.85 Percent between the Estimated and Actual EPS. Hence, the surprise factor was -17.9 percent.
Analysts estimated $-4.55/share for the previous Quarter, where Roka Bioscience, Inc. (NASDAQ:ROKA) reported Actual EPS of $-4.7/share with the difference of -0.15 percent and a surprise of -3.3 percent.
The 1 analysts offering 12-month price forecasts for Roka Bioscience Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +66.67% increase from the last price of 6.00.
While Looking at Sales Growth (Year/est), the company is currently showing a percentage value of 17.9 percent.
Roka Bioscience, Inc. (NASDAQ:ROKA) topped its 52-week high price target of 7.37 on Oct 12, 2016. The company reached a 52-week low at 0.5 on Feb 17, 2016.
The company’s stock currently has 10.62 Million in market capitalization. The volatility rate is 14.02% percent and 8.98% percent each. Price per earning (ttm) stands at 0.
This year, the company showed a solid 17.9 percent of growth. The next year’s growth is calculated to be 74.2 percent. The company projects a long term annual growth estimate of 35 percent.
Roka Bioscience, Inc. is a molecular diagnostics company. It is focused on developing and commercializing advanced testing solutions for the food safety testing market. Roka provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. Roka Bioscience, Inc. is headquartered in Warren, New Jersey.